Lifetech Scientific
Explore the latest insights on Lifetech Scientific and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lifetech Scientific’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that HS‑10374, its in‑house‑developed selective allosteric inhibitor of tyrosine kinase 2 (TYK2), met co‑primary endpoints and multiple secondary endpoints in the pivotal…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
